natgillin/translations-raw huggingface dataset:
Co-administration of robenacoxib tablets with one third of the daily food ration produced no change in Tmax (0.5 h), Cmax (1,201 ng/ml) or AUC (1383 ng·h/ml). 
Vnos tablet robenakoksiba s tretjino dnevnega obroka hrane ni povzročil bistvenih sprememb pri Tmax (0,5 h), Cmax (1201 ng/ml) ali
Cardboard box containing 6 x 1, 12 x 1, 30 x 1 or 60 x 1 tablets in Alu/Alu perforated unit dose blisters. 
Kartonska škatla s 6 x 1, 12 x 1, 30 x 1 ali 60 x 1 tableto v perforiranem Alu/Alu deljivem pretisnem omotu s posameznimi odmerki.
Treatment should be discontinued after 10 days if no clinical improvement is apparent. 
V kolikor po 10 dneh ni kliničnega izboljšanja, z zdravljenjem prekinite.
NAME OF THE VETERINARY MEDICINAL PRODUCT Onsior 20 mg/ml solution for injection for cats and dogs Robenacoxib 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Onsior 20 mg/ml raztopina za injiciranje za mačke in pse robenakoksib
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Wash hands and exposed skin immediately after use of the veterinary medicinal product. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: Po uporabi zdravila si takoj umijte roke in izpostavljeno kožo.
For the reduction of moderate pain and inflammation associated with orthopaedic surgery in cats. 
Za zmanjšanje zmerne bolečine in vnetja v povezavi z ortopedskimi operativnimi posegi pri mačkah.
Round, beige to brown tablets with imprints “NA” on one side and “AK” on the other side. 
Okrogle, bež do rjave tablete z vtisnjenima oznakama »NA« na eni in »AK« na drugi strani.
After oral administration of robenacoxib tablets at approximately 2 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h, a Cmax of 1,159 ng/ml and an AUC of 1,337 ng·h/ml. 
Po peroralnem vnosu tablet robenakoksiba v približnem odmerku 2 mg/kg telesne mase brez hrane je maksimalna koncentracija v krvi hitro dosežena s Tmax 0,5 h, Cmax 1159 ng/ml in površino pod krivuljo koncentracije v krvi v odvisnosti od časa (AUC) 1337 ng·h/ml.
Round, beige to brown tablets with the imprint “NA” on one side and the following imprint on the other side: 
Okrogle, bež do rjave tablete z vtisnjeno oznako »NA« na eni strani in z naslednjimi vtisnjenimi oznakami na drugi strani:
Apart from one lactam metabolite, the identity of other metabolites is not known in cats or dogs. 
Z izjemo enega laktamskega presnovka ostali presnovki pri mačkah in psih niso znani.
For pregnant women, particularly near term pregnant women, accidental injection and prolonged dermal exposure increases the risk for premature closure of the ductus arteriosus in the foetus. 
Pri nosečnicah, zlasti blizu roka poroda, nenamerno injiciranje in dolgotrajnejše izpostavljanje kože zdravilu poveča tveganje za predčasno zaprtje duktusa arteriozusa pri plodu.
Reversible, minimal injection site reactions were noted in both dose groups. 
Pri obeh skupinah je bilo opaziti minimalno reakcijo na mestu vboda, ki pa je bila reverzibilna.
Diarrhoea or vomiting with blood were uncommon. 
Diareja in bruhanje s prisotnostjo krvi sta bila opisana občasno.
NATURE/TYPE: Cardboard box 
VRSTA/TIP: Pretisni omot
Apart from one lactam metabolite, the identity of other metabolites is not known in dogs. 
Z izjemo enega laktamskega presnovka ostali presnovki pri psih niso znani.
Vomiting was very commonly reported, and anorexia, diarrhoea, lethargy and inappropriate defecation were commonly reported in field studies with treatment up to 12 weeks in cats with chronic musculo-skeletal disorder, with similar frequencies in the Onsior and placebo treated cats. 
V terenskih študijah z zdravljenjem do 12 tednov pri mačkah s kroničnim mišičnoskeletnim obolenjem so zelo pogosto poročali o bruhanju, pogosto pa o anoreksiji, diareji, letargiji in neustreznem iztrebljanju, s podobno pogostostjo pri mačkah, zdravljenih z zdravilom Onsior, in tistih, zdravljenih s placebom.
PACKAGE LEAFLET: Onsior 20 mg/ml solution for injection for cats and dogs 
Onsior 20 mg/ml raztopina za injiciranje za mačke in pse
In healthy young dogs aged 6 months, once daily subcutaneous administration of robenacoxib at doses of 2 (recommended therapeutic dose; RTD), 6 (3 times RTD), and 20 mg/kg (10 times RTD) for 9 administrations over a 5 week period (3 cycles of 3 consecutive once daily injections) did not produce any signs of toxicity, including gastrointestinal, kidney or liver toxicity and had no effect on bleeding time. 
Pri zdravih psih, starih 6 mesecev, se po 5 tednih subkutanega prejemanja 9 odmerkov (3 ciklov 3 zaporednih injekcij enkrat dnevno) robenakoksiba v odmerkih 2 mg/kg (priporočen terapevtski odmerek; PTO), 6 mg/kg (3-kratni PTO) in 20 mg/kg (10-kratni PTO) znaki toksičnosti na prebavilih, ledvicah ali jetrih niso pojavili, prav tako ni bilo vpliva na čas krvavitve.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Wash hands after use of the veterinary medicinal product. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: Po uporabi zdravila si umijte roke.
In clinical trials in cats this product reduced pain and inflammation associated with acute musculo-skeletal disorders and reduced the need for rescue treatment when given as premedication in case of orthopaedic surgery, in combination with opioids. 
To zdravilo je v kliničnih preizkusih pri mačkah zmanjšalo bolečino in vnetje v povezavi z akutnimi mišičnoskeletnimi obolenji ter potrebo po uporabi drugih hitro delujočih zdravil za lajšanje bolečin, kadar so ga dajali kot premedikacijo v kombinaciji z opioidi v primeru ortopedskih operativnih posegov.
After oral administration of robenacoxib flavoured tablets at 1 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h, a Cmax of 1,124 ng/ml and an AUC of 1,249 ng·h/ml. 
Po peroralnem vnosu robenakoksib tablet z okusom, v priporočenem odmerku 1 mg/kg telesne mase brez hrane, je maksimalna koncentracija v krvi hitro dosežena s Tmax 0,5 h, Cmax 1124 ng/ml in površino pod krivuljo koncentracije v krvi v odvisnosti od časa (AUC) 1249 ng·h/ml.
Regular monitoring should be undertaken by the veterinarian. 
Potreben je reden veterinarski nadzor.
Vomiting was very commonly reported, and anorexia, diarrhoea, lethargy and inappropriate defecation were commonly reported in field studies with treatment up to 3 months in cats with chronic musculo-skeletal disorder, with similar frequencies in the Onsior and placebo treated cats. 
V terenskih študijah z zdravljenjem do 3 mesece pri mačkah s kroničnim mišičnoskeletnim obolenjem so zelo pogosto poročali o bruhanju, pogosto pa o anoreksiji, diareji, letargiji in neustreznem iztrebljanju, s podobno pogostostjo pri mačkah, zdravljenih z zdravilom Onsior, in tistih, zdravljenih s placebom.
5 mg tablets: Robenacoxib 5 mg 10 mg tablets: Robenacoxib 10 mg 20 mg tablets: Robenacoxib 20 mg 40 mg tablets: Robenacoxib 40 mg 
5 mg tablete: robenakoksib 5 mg 10 mg tablete: robenakoksib 10 mg 20 mg tablete: robenakoksib 20 mg 40 mg tablete: robenakoksib 40 mg
MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
PROIZVAJALCI ZDRAVILA, ODGOVORNI ZA SPROŠČANJE SERIJ
Cardboard box containing 7, 14, 28 or 70 tablets in Alu/Alu blisters, 30 x 1 tablets in Alu/Alu perforated unit dose blisters or 60 x 1 tablets in Alu/Alu perforated unit dose blisters. 
Kartonska škatla s 7, 14, 28 ali 70 tabletami v Alu/Alu pretisnem omotu, 30 x 1 tableto v perforiranem Alu/Alu deljivem pretisnem omotu s posameznimi odmerki ali 60 x 1 tableto v perforiranem Alu/Alu deljivem pretisnem omotu s posameznimi odmerki.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: 
Vsak ml vsebuje:
For the treatment of pain and inflammation associated with chronic osteoarthritis in dogs. 
Za zdravljenje bolečine in vnetja v povezavi s kroničnim osteoartritisom pri psih.
At dosages ranging from 0.25 to 4 mg/kg, robenacoxib had analgesic, anti-inflammatory and anti-pyretic effects in an inflammation model with a rapid onset of action (1 h). 
4 mg/kg je robenakoksib pri vnetnem modelu učinkoval protibolečinsko, protivnetno in antipiretično, s hitrim nastopom učinka (1 h).
Do not use in case of hypersensitivity to the active substance or to any of the excipients. 
Ne uporabite v primerih preobčutljivosti na učinkovino ali na katerokoli pomožno snov.
Symptomatic, supportive therapy is recommended and should consist of administration of gastrointestinal protective agents and infusion of isotonic saline. 
Posebnega antidota ni. Priporočljiva je podporna simptomatska terapija, ki naj vključuje zdravila za zaščito želodčne in črevesne sluznice ter infuzijo izotonične fiziološke raztopine.
Co-administration of robenacoxib tablets with the entire daily food ration produced no delay in Tmax (0.5 h), but a lower Cmax (691 ng/ml) 
Pri vnosu tablet robenakoksiba s celotnim dnevnim obrokom hrane ni prišlo do podaljšanja pri Tmax (0,5 h), ampak nižje Cmax (691 ng/ml) in rahlo nižje AUC (1069 ng·h/ml).
Do not use in cats suffering from ulceration in the digestive tract. 
Ne uporabite pri mačkah z razjedami na prebavilih.
The interchangeable use of Onsior tablets and Onsior solution for injection in 4-months old cats at overdoses of up to 3 times the maximum recommended dose (2.4 mg, 4.8 mg, 7.2 mg robenacoxib/kg orally and 2.0 mg, 4.0 mg and 6.0 mg robenacoxib/kg subcutaneously) resulted in a dose-dependent increase of sporadic oedema at the injection site and minimal to mild subacute/chronic inflammation of the subcutaneous tissue. 
Kot rezultat zamenljive uporabe zdravila Onsior tablete in zdravila Onsior raztopina za injiciranje sta se pri mačkah, starih 4 mesece, pri prevelikem odmerku do 3-kratnih najvišjih priporočljivih odmerkov (2,4 mg, 4,8 mg, 7,2 mg robenakoksiba na kg telesne mase peroralno in 2,0 mg, 4,0 mg in
EXPIRY DATE EXP {month/year} Once broached, use by … 
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP: {mesec/leto}
Robenacoxib had analgesic and anti-inflammatory actions in an inflammation model in dogs with single oral doses ranging from 0.5 to 8 mg/kg, with an ID50 of 0.8 mg/kg and a rapid onset of action (0.5 h). 
Pri vnetnem modelu pri psih so enkratni peroralni odmerki robenakoksiba od 0,5 do 8 mg/kg telesne mase z ID50 0,8 mg/kg učinkovali hitro (0,5 h) protibolečinsko in protivnetno.
Apart from one lactam metabolite, the identity of other metabolites is not known in cats. 
Z izjemo enega laktamskega presnovka ostali presnovki pri mačkah niso znani.
NATURE/TYPE: Blister foil 
OVOJNINAH VRSTA/TIP: Steklena viala
In cats robenacoxib is extensively metabolised by the liver. 
Robenakoksib se pri mačkah presnavlja v veliki meri v jetrih.
Onsior tablets for cats are available in cardboard boxes containing 6 x 1, 12 x 1, 30 x 1 or 60 x 1 tablets in Alu/Alu perforated unit dose blisters.. Not all pack sizes may be marketed. 
Zdravilo Onsior tablete za mačke je na voljo v kartonskih škatlah s 6 x 1, 12 x 1, 30 x 1 ali 60 x 1 tableto v perforiranem Alu/Alu deljivem pretisnem omotu s posameznimi odmerki.
Onsior tablets for dogs are available in cardboard boxes containing 7, 14, 28 or 70 tablets in Alu/Alu blisters, 30 x 1 tablets in Alu/Alu perforated unit dose blisters or 60 x 1 tablets in Alu/Alu perforated unit dose blisters.. Not all pack sizes may be marketed. 
Zdravilo Onsior tablete za pse je na voljo v kartonskih škatlah s 7, 14, 28 ali 70 tabletami v Alu/Alu pretisnem omotu, 30 x 1 tableto v perforiranem Alu/Alu deljivem pretisnem omotu s posameznimi odmerki ali 60 x 1 tableto v perforiranem Alu/Alu deljivem pretisnem omotu s posameznimi odmerki.
THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN” Keep out of the sight and reach of children. 
BESEDILO "ZDRAVILO SHRANJUJTE NEDOSEGLJIVO OTROKOM” Zdravilo shranjujte nedosegljivo otrokom.
Repeated oral administration of robenacoxib to dogs at dosages of 2-10 mg/kg for 6 months produced no change in the blood profile, with neither accumulation of robenacoxib nor enzyme induction. 
Ponavljajoče se 6 mesecev trajajoče peroralno prejemanje robenakoksiba v priporočenih odmerkih 2-10 mg/kg telesne mase pri psih ni povzročilo sprememb v krvni sliki,
The safety of the veterinary medicinal product has not been established in cats less than 4 months of age and in dogs less than 2 months of age, or in cats or dogs less than 2.5 kg body weight. 
Varnost zdravila za uporabo v veterinarski medicini ni bila dokazana pri mačkah, mlajših od 4 mesecev, in psih, mlajših od 2 mesecev, oziroma pri mačkah ali psih, lažjih od 2,5 kg telesne mase.
Use in cats with impaired cardiac, renal or hepatic function or in cats that are dehydrated, hypovolaemic or hypotensive may involve additional risks. 
Uporaba pri mačkah z oslabljenim srčnim, ledvičnim ali jetrnim delovanjem oziroma pri dehidriranih, hipovolemičnih ali hipotenzivnih mačkah predstavlja dodatno tveganje.
In artificially induced inflammation in dogs, robenacoxib reduced pain and inflammation with single oral doses ranging from 0.5 to 8 mg/kg and a rapid onset of action (0.5 h). 
(0,5 h) in zmanjšal bolečino in vnetje z enkratnimi peroralnimi odmerki od 0,5 do 8 mg/kg.
Therapy should be discontinued if liver enzyme activities increase markedly or the dog shows clinical signs such as anorexia, apathy or vomiting in combination with elevated liver enzymes. 
V primeru vidnega porasta aktivnosti jetrnih encimov oziroma kadar so pri psu vidni klinični znaki anoreksije, apatije ali bruhanja v kombinaciji s povišanimi jetrnimi encimi, je treba zdravljenje prekiniti.
Robenacoxib is excreted predominantly via the biliary route (∼70%) rather than via the kidneys (∼30%). 
Pretežno se izloča z žolčem (∼ 70 %), v približno 30 % pa preko ledvic.
Do not use in animals suffering from gastrointestinal ulceration. 
Ne uporabite pri živalih z razjedami na prebavilih.
Adverse reactions of the digestive tract (such as vomiting) were commonly reported but most cases were mild and recovered without treatment. 
Neželeni učinki na prebavilih (kot je bruhanje) so bili opisani pogosto, vendar so bili v večini primerov blagi in so izzveneli brez zdravljenja.
Use in animals with impaired cardiac, renal or hepatic function or those are dehydrated, hypovolaemic or hypotensive may involve additional risks. 
Uporaba pri živalih z oslabljenim srčnim, ledvičnim ali jetrnim delovanjem oziroma pri dehidriranih, hipovolemičnih ali hipotenzivnih živalih predstavlja dodatno tveganje.
In dogs, robenacoxib was in vitro approximately 140 fold selective for COX-2 (IC50 0.04 μM) as compared to COX-1 (IC50 7.9 μM). 
Pri psih je bila selektivnost robenakoksiba in vitro približno 140-krat večja za COX-2 (IC50 0,04 μM)
Onsior 5 mg tablets for dogs: 
Onsior 5 mg tablete za pse:
In healthy young cats aged 7- 8 months, oral robenacoxib administered at overdoses of up to 5 times the maximum recommended dose (2.4 mg, 7.2 mg, 12 mg robenacoxib/kg bodyweight) for 6 months was well tolerated. 
mesecev v prevelikih odmerkih do 5-kratnih najvišjih priporočljivih odmerkov (2,4 mg, 7,2 mg, 12 mg robenakoksiba na kg telesne mase), dobro prenašale.
Do not use in pregnant or lactating cats or cats used for breeding because the safety of this product has not been established in these animals. 
Ne uporabite pri mačkah v obdobju brejosti in laktacije ali pri mačkah, namenjenih za vzrejo, ker varnost robenakoksiba pri teh živalih ni bila ugotovljena.
Do not use in case of hypersensitivity to robenacoxib or to any ingredients of the solution. 
Ne uporabite v primerih preobčutljivosti na robenakoksib ali na katerokoli sestavino raztopine.
For the treatment of pain and inflammation associated with orthopaedic or soft tissue surgery in dogs. 
Za zdravljenje bolečine in vnetja v povezavi z ortopedskimi operativnimi posegi ali z operativnimi posegi na mehkih tkivih pri psih.
Mild and transient diarrhoea, soft faeces or vomiting were commonly reported in clinical trials with treatment up to 6 days. 
V kliničnih preizkusih z zdravljenjem do 6 dni so bili pogosto opisani blaga in prehodna diareja, mehko blato ali bruhanje.
Robenacoxib is extensively metabolised by the liver in cats and dogs. 
Robenakoksib se pri mačkah in psih presnavlja v veliki meri v jetrih.
Onsior 20 mg tablets for dogs: 
Onsior 20 mg tablete za pse:
Solution for injection: Elanco France S.A.S 26 Rue de la Chapelle 68330 Huningue FRANCE 
26 Rue de la Chapelle 68330 Huningue FRANCIJA
Use in dogs with impaired cardiac or renal function or dogs that are dehydrated, hypovolaemic or hypotensive may involve additional risks. 
Uporaba pri psih z oslabljenim srčnim, ledvičnim delovanjem oziroma pri dehidriranih, hipovolemičnih ali hipotenzivnih psih predstavlja dodatno tveganje.
Robenacoxib is extensively metabolised by the liver in dogs. 
Robenakoksib se pri psih presnavlja v veliki meri v jetrih.
For pregnant women, particularly near term pregnant women, prolonged dermal exposure increases the risk of premature closure of the ductus arteriosus in the foetus. 
Dolgotrajnejše izpostavljanje kože zdravilu pri nosečnicah, zlasti blizu roka poroda, poveča tveganje za predčasno zaprtje duktusa arteriozusa pri plodu.
No changes in the QT interval were observed after a single intravenous administration of 2 or 4 mg/kg robenacoxib to anaesthetised healthy cats. 
Po enkratnem intravenskem dajanju 2 ali 4 mg/kg robenakoksiba anesteziranim zdravim mačkam niso opazili sprememb v QT intervalu.
Onsior 40 mg tablets for dogs: 
Onsior 40 mg tablete za pse:
For the treatment of pain and inflammation associated with orthopaedic or soft tissue surgery in cats. 
Za zdravljenje bolečine in vnetja v povezavi z ortopedskimi operativnimi posegi ali z operativnimi posegi na mehkih tkivih pri mačkah.
Special precautions to be taken by the person administering the veterinary medicinal product to animals Wash hands after use of the veterinary medicinal product. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Po uporabi zdravila si umijte roke.
The safety of the veterinary medicinal product has not been established in dogs weighing less than 2.5 kg or under 3 months of age. 
Varnost zdravila za uporabo v veterinarski medicini ni bila dokazana pri psih, lažjih od 2,5 kg telesne mase oziroma mlajših od 3 mesecev.
Onsior 10 mg tablets for dogs: 
Onsior 10 mg tablete za pse:
None. 
Ga ni.
The safety of the veterinary medicinal product has not been established in cats weighing less than 2.5 kg or under 4 months of age. 
Varnost zdravila za uporabo v veterinarski medicini ni bila dokazana pri mačkah, lažjih od 2,5 kg telesne mase oziroma mlajših od 4 mesecev.
Adverse reactions of the digestive tract were reported very commonly, but most cases were mild and recovered without treatment. 
Zelo pogosto so bili opisani neželeni učinki na prebavilih, ki pa so bili v večini primerov blagi in so izzveneli brez zdravljenja.
4.8 Interaction with other medicinal products and other forms of interaction 
4.8 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Zdravilo Onsior se ne sme uporabljati skupaj z drugimi zdravili iz skupine NSAID.
Robenacoxib 
robenakoksib
As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised cats. 
Pri občutljivih ali ogroženih mačkah je lahko prevelik odmerek, tako kot pri drugih zdravilih iz skupine NSAID, toksičen za prebavila, ledvice ali jetra.
EU/2/08/089/016 (7 tablets) EU/2/08/089/017 (14 tablets) EU/2/08/089/018 (28 tablets) EU/2/08/089/019 (70 tablets) EU/2/08/089/028 (30 x 1 tablets) EU/2/08/089/029 (60 x 1 tablets) 
EU/2/08/089/016 (7 tablet) EU/2/08/089/017 (14 tablet) EU/2/08/089/018 (28 tablet) EU/2/08/089/019 (70 tablet) EU/2/08/089/028 (30 x 1 tableta) EU/2/08/089/029 (60 x 1 tableta)
EU/2/08/089/012 (7 tablets) EU/2/08/089/013 (14 tablets) EU/2/08/089/014 (28 tablets) EU/2/08/089/015 (70 tablets) EU/2/08/089/026 (30 x 1 tablets) EU/2/08/089/027 (60 x 1 tablets) 
EU/2/08/089/012 (7 tablet) EU/2/08/089/013 (14 tablet) EU/2/08/089/014 (28 tablet) EU/2/08/089/015 (70 tablet) EU/2/08/089/026 (30 x 1 tableta) EU/2/08/089/027 (60 x 1 tableta)
Robenacoxib produced marked inhibition of 
akumulacije robenakoksiba ali indukcije encimov.
As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised animals. 
Pri občutljivih ali ogroženih živalih je lahko prevelik odmerek, tako kot pri drugih zdravilih iz skupine NSAID, toksičen za prebavila, ledvice ali jetra.
EU/2/08/089/008 (7 tablets) EU/2/08/089/009 (14 tablets) EU/2/08/089/010 (28 tablets) EU/2/08/089/011 (70 tablets) EU/2/08/089/024 (30 x 1 tablets) EU/2/08/089/025 (60 x 1 tablets) 
EU/2/08/089/008 (7 tablet) EU/2/08/089/009 (14 tablet) EU/2/08/089/010 (28 tablet) EU/2/08/089/011 (70 tablet) EU/2/08/089/024 (30 x 1 tableta) EU/2/08/089/025 (60 x 1 tableta)
EU/2/08/089/004 (7 tablets) EU/2/08/089/005 (14 tablets) EU/2/08/089/006 (28 tablets) EU/2/08/089/007 (70 tablets) EU/2/08/089/022 (30 x 1 tablets) EU/2/08/089/023 (60 x 1 tablets) 
EU/2/08/089/004 (7 tablet) EU/2/08/089/005 (14 tablet) EU/2/08/089/006 (28 tablet) EU/2/08/089/007 (70 tablet) EU/2/08/089/022 (30 x 1 tableta) EU/2/08/089/023 (60 x 1 tableta)
Use this veterinary medicinal product under strict veterinary monitoring in animals at risk of ulceration of the digestive tract, or if the animal previously displayed intolerance to other NSAIDs. 
Pri živalih s tveganjem za nastanek razjed na prebavilih oziroma z znano preobčutljivostjo na druga zdravila iz skupine NSAID uporabite to zdravilo pod strogim veterinarskim nadzorom.
For pregnant women, particularly near term pregnant women, accidental injection and prolonged dermal exposure might increase the risk to the foetus. 
Nenamerno injiciranje in dolgotrajnejše izpostavljanje kože zdravilu pri nosečnicah, zlasti blizu roka poroda, lahko poveča tveganje za plod.
METHOD AND ROUTE(S) OF ADMINISTRATION Subcutaneous use. 
4.9 Odmerjanje in pot uporabe Subkutana uporaba.
Use this veterinary medicinal product under strict veterinary monitoring in cats with a risk of gastrointestinal ulcers, or if the cat previously displayed intolerance to other NSAIDs. 
Pri mačkah s tveganjem za nastanek razjed na prebavilih oziroma z znano preobčutljivostjo na druga zdravila iz skupine NSAID uporabite to zdravilo pod strogim veterinarskim nadzorom.
26 Rue de la Chapelle 
26 Rue de la Chapelle 68330 Huningue
For pregnant women, particularly near term pregnant women, prolonged dermal exposure may increase the risk to the foetus. 
Dolgotrajnejše izpostavljanje kože zdravilu pri nosečnicah, zlasti blizu roka poroda, poveča tveganje za plod.
Use this product under strict veterinary monitoring in dogs with a risk of gastrointestinal ulcers, or if the dog previously displayed intolerance to other NSAIDs. 
Pri psih s tveganjem za nastanek razjed na prebavilih oziroma z znano preobčutljivostjo na druga zdravila iz skupine NSAID uporabite to zdravilo pod strogim veterinarskim nadzorom.
In clinical trials at the recommended dose (2 mg/kg), robenacoxib reduced pain and inflammation in dogs undergoing orthopaedic or soft tissue surgery. 
(2 mg/kg) zmanjšal bolečino in vnetje pri psih, podvrženih ortopedskim operativnim posegom ali operativnim posegom na mehkih tkivih.
Do not use after the expiry date stated on the label after EXP. After first broaching of the vial, the product may be stored for 28 days. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini za oznako »EXP«.
In healthy young dogs aged 5-6 months, oral robenacoxib administered at high overdoses (4, 6 or 10 mg/kg/day for 6 months) did not produce any signs of toxicity, including no evidence of any gastrointestinal, kidney or liver toxicity and no effect on bleeding time. 
(4, 6 ali 10 mg/kg/dan) niso pojavili znaki toksičnosti na prebavilih, ledvicah ali jetrih, prav tako ni bilo vpliva na čas krvavitve.
In healthy young cats aged 7-8 months, oral robenacoxib administered at high overdoses (4, 12 or 20 mg/kg/day for 6 weeks) did not produce any signs of toxicity, including no evidence of any gastrointestinal, kidney or liver toxicity and no effect on bleeding time. 
(4, 12 ali 20 mg/kg/dan) niso pojavili znaki toksičnosti na prebavilih, ledvicah ali jetrih, prav tako ni bilo vpliva na čas krvavitve.